高遗传风险可预测代谢功能障碍相关脂肪性肝病患者纤维化随年龄增长而加重
这项横断面研究纳入570例前瞻性招募的代谢功能障碍相关脂肪性肝病(MASLD)成人,采用磁共振弹性成像(MRE)和基因分型评估遗传风险评分与肝硬度随年龄变化的关系,并在拉丁美洲外部队列中验证。高遗传风险组肝硬度每增加10岁升高(β=0.28 kPa,95%CI 0.12-0.44,p=0.001),低风险组无此差异,PNPLA3 G/G基因型在44岁时肝硬度显著更高。
要点
- 高遗传风险组肝硬度每10年增加0.28 kPa(95%CI 0.12-0.44,p=0.001),低风险组无此变化。
- PNPLA3 G/G基因型者肝硬度随年龄升高更明显,44岁时显著高于其他基因型。
- 评估MASLD患者遗传风险有助于识别需要更频繁监测的高危人群。
核心结论
- 遗传风险评分、PRS-HFC、PRS-5及PNPLA3基因型单独均与纤维化严重程度每十年增加相关,导致中年起疾病轨迹出现分化。
研究设计与样本
- 横断面研究,前瞻性招募18-70岁MASLD成人570例,接受磁共振弹性成像(MRE)和PNPLA3、TM6SF2、MBOAT7、GCKR、HSD17B13基因分型。
- 遗传风险评分(GRS)为PNPLA3风险等位基因减去HSD17B13保护变异之和(0=低风险,1=高风险),并估算PRS-HFC和PRS-5。
- 主要终点为按GRS分组的MRE肝硬度测量值(LSM)随年龄的变化,并使用拉丁美洲外部队列验证。
主要发现
- 570例参与者中位年龄57[49-64]岁,女性占56.8%,西班牙裔占34.2%,中位MRE为2.4[2.1-3.0] kPa,51%为高GRS。
- 高GRS组LSM随年龄每增加10岁升高(β=0.28 kPa,95%CI 0.12-0.44,p=0.001),低GRS组无此差异。
- PRS-HFC和PRS-5得到类似结果。
- PNPLA3基因型单独预测更高LSM:C/G型β=0.32 kPa(95%CI 0.02-0.61,p=0.034),G/G型β=0.87 kPa(95%CI 0.52-1.22,p<0.0001)。
- G/G基因型在44岁时LSM显著更高,验证人群中结果一致。
临床怎么用
- 作者认为,评估MASLD患者的遗传风险有助于识别需要更频繁监测的高危患者。
- 作者指出,将遗传风险评估纳入MASLD管理可早期识别可能受益于更频繁监测和靶向干预的高危个体。
- 作者建议,临床医生、研究人员和政策制定者可考虑将遗传分层整合到现有风险评估框架中,以优化筛查和监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Limited data have prevented routine genetic testing from being integrated into clinical practice in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to quantify the effect of genetic variants on changes in fibrosis severity per decade in patients with MASLD. METHODS: This cross-sectional study included prospectively recruited adults with MASLD aged 18-70 who underwent magnetic resonance elastography (MRE) and genotyping for PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13. A genetic risk score (GRS) was calculated as the sum of established risk alleles in PNPLA3 minus protective variants in HSD17B13 (0 = low risk, 1 = high risk). We also estimated the polygenic risk score-hepatic fat content (PRS-HFC) and the adjusted version (PRS-5). The primary endpoint was the age-related change in liver stiffness measurement (LSM) on MRE by GRS. Findings were validated using an external cohort from Latin America. RESULTS: Among 570 participants, the median age was 57 [49-64] years, 56.8% were women, and 34.2% were Hispanic. Median MRE was 2.4 [2.1-3.0] kPa, and 51% had a high GRS. In the high GRS group, LSM increased per 10-year age increase (β = 0.28 kPa, 95% CI 0.12-0.44, p = 0.001), while no such difference was observed in the low GRS group. Similar findings were observed using PRS-HFC and PRS-5. PNPLA3 genotype alone also predicted higher LSM (C/G: β = 0.32 kPa, 95% CI 0.02-0.61, p = 0.034; G/G: β = 0.87 kPa, 95% CI 0.52-1.22, p <0.0001) and the G/G genotype was associated with a significantly higher LSM by age 44, which was consistent in the validation population. CONCLUSION: GRS, PRS-HFC, PRS-5, and PNPLA3 genotypes alone are associated with increased fibrosis severity per decade, resulting in divergent disease trajectories starting in midlife. Assessing genetic risk in MASLD will identify high-risk patients who require more frequent monitoring. IMPACT AND IMPLICATIONS: This study provides granular evidence that genetic predisposition, particularly the PNPLA3 G/G genotype, significantly influences the trajectory of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with a more pronounced impact emerging after the fourth decade of life. These findings highlight the importance of incorporating genetic risk assessment into MASLD management, as it allows for the early identification of high-risk individuals who may benefit from more frequent monitoring and targeted interventions. Given the rising global burden of MASLD, clinicians, researchers, and policymakers should consider integrating genetic stratification into existing risk assessment frameworks to refine screening and surveillance strategies. By optimizing patient selection for non-invasive fibrosis assessment and potential therapeutic interventions, this approach could enhance precision medicine efforts and may improve long-term outcomes.
引用
- Díaz LA, Alazawi W, Agrawal S, et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J Hepatol. 2025. PMID: 40334848. doi:10.1016/j.jhep.2025.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。